SynthesisPhytotherapy research : PTR2025
Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta-Analysis, Network Pharmacology, and Mendelian Randomization.
Synthesis in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With Meta-Analysis, Network Pharmacology, and Mendelian Randomization.Phytotherapy research : PTR · 2025Pooled it
- Bioavailable testosterone reduces the risk of lung squamous cell carcinoma: a comprehensive data study.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To evaluate the efficacy and explore the potential mechanism of curcumin for the treatment and prevention of NSCLC. We searched six databases thoroughly for articles published before December 2024. Stata 15.0 software was applied for systematic review with meta-analysis. We utilized network pharmacology, Mendelian randomization, and molecular docking techniques to investigate the pharmacological properties and potential targets of curcumin in the treatment of NSCLC. Twenty-four studies involving 392 experimental animals were included in this study. Meta-analysis results showed that curcumin significantly reduced tumor volume of mice (p < 0.001) in the NSCLC group compared to the control group. Two hundred twenty-nine curcumin target genes were predicted. 1546 NSCLC-related genes were obtained by taking the intersection of DEGs and genes in the key module of WGCNA. Eight hub genes were identified by protein-protein interaction. The eight hub genes showed significant clinical value and were found to be negatively correlated with the majority of immune cell infiltration. Molecular docking results indicated a good binding affinity between these eight hub genes and curcumin. Mendelian randomization demonstrated a causal relationship between the AURKB level and the increased risk of NSCLC. In this study, the effectiveness of curcumin has been demonstrated in in vivo models of NSCLC by meta-analysis. AURKB has been identified as a high-risk target for NSCLC by network pharmacological analysis and MR for the first time. Our study provides a scientific basis for clinical applications of curcumin in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.